Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Site search
Search
Toggle navigation
Contact Us
Subscribe
Promote Your Event
e-Edition
Privacy Policy
Terms of Service
Local Weather
Home Delivery
Submission Forms
News
Local News
The Leader
Heartland News
Sports
Entertainment
Local Events
Multimedia
Photo Galleries
Videos
Obituaries
Classifieds
Real Estate
Property for Rent
Cars & Vehicles
Jobs
Items for Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place an ad
Legals
Best of 2022
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Agios Pharmaceuticals
(NQ:
AGIO
)
23.26
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 17, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
23.26
Bid (Size)
9.540 (1)
Ask (Size)
24.52 (3)
Prev. Close
23.26
Today's Range
23.26 - 23.26
52wk Range
16.75 - 34.76
Shares Outstanding
58,951,469
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
Top News
More News
7 Biotech Stocks That Could Be the Next Big Thing
March 15, 2023
Although speculation might be a tough call at this juncture, these biotech stocks and their underlying science might be compelling enough.
Via
InvestorPlace
Agios Pharmaceuticals's Return On Capital Employed Insights
February 24, 2023
Via
Benzinga
Performance
YTD
-15.51%
-15.51%
1 Month
-15.97%
-15.97%
3 Month
-17.08%
-17.08%
6 Month
-28.28%
-28.28%
1 Year
-18.47%
-18.47%
More News
Read More
Benzinga's Top Ratings Upgrades, Downgrades For February 3, 2023
February 03, 2023
Via
Benzinga
Agios Pharmaceuticals's Return On Capital Employed Overview
November 17, 2022
Via
Benzinga
Looking Into Agios Pharmaceuticals Return On Capital Employed
August 15, 2022
Via
Benzinga
Agios Is Looking For Development Partner, Lays Off Exploratory Research Staff
May 17, 2022
Via
Benzinga
7 Analysts Have This to Say About Agios Pharmaceuticals
May 17, 2022
Via
Benzinga
3 Under-the-Radar Biotech Stocks to Buy in 2022
December 24, 2022
Via
The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For November 17, 2022
November 17, 2022
Via
Benzinga
Agios Pharmaceuticals: Q1 Earnings Insights
May 05, 2022
Via
Benzinga
Europe Approves Agios Pharma's Mitapivat For Adult Pyruvate Kinase Deficiency Patients
November 11, 2022
Via
Benzinga
Agios Pharmaceuticals: Q3 Earnings Insights
November 03, 2022
Via
Benzinga
Agios Pharmaceuticals Stock Clears Key Benchmark, Hitting 90-Plus RS Rating
September 02, 2022
Via
Investor's Business Daily
Nutanix, Five Below And Some Other Big Stocks Moving Higher On Thursday
September 01, 2022
Via
Benzinga
Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate
August 04, 2022
Via
Benzinga
Why Snap Shares Jumped 7%; Here Are 75 Biggest Movers From Yesterday
September 02, 2022
Via
Benzinga
Agios Pharmaceuticals: Q2 Earnings Insights
August 04, 2022
Via
Benzinga
Why Okta Is Trading Lower By Over 32%, Here Are 58 Stocks Moving In Thursday's Mid-Day Session
September 01, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 27, 2022
July 27, 2022
Via
Benzinga
The Daily Biotech Pulse: AstraZeneca's COVID-19 Vaccine As Effective As mRNA Shots, Humanigen's Lenzilumab Disappoints In COVID-19 Study, Positive Preclinical Data From Hoth's Alzheimer's Program
July 13, 2022
Via
Benzinga
U.S. Stock Futures Higher; All Eyes On Inflation Data
July 13, 2022
Via
Benzinga
Delta Air Lines, Fastenal And 3 Stocks To Watch Heading Into Wednesday
July 13, 2022
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
June 27, 2022
Via
Benzinga
Stocks That Hit 52-Week Lows On Friday
May 27, 2022
Via
Benzinga
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study
May 05, 2022
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.